This prospective observational study aims to evaluate the clinical value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC). Patients diagnosed with LS-SCLC at Shandong Cancer Hospital and Institute underwent \[18F\]AlF-NOTA-QHY-04 PET/CT imaging before receiving standard concurrent chemoradiotherapy. Imaging findings were analyzed and correlated with clinical outcomes, including progression-free survival, to explore the potential role of CXCR4 PET/CT as a prognostic imaging biomarker. The results of this study may help improve risk stratification and outcome prediction in patients with limited-stage small cell lung cancer.
This was a single-center, prospective observational study conducted at Shandong Cancer Hospital and Institute to investigate the prognostic value of CXCR4-targeted PET/CT imaging in patients with limited-stage small cell lung cancer (LS-SCLC). Eligible patients with histologically confirmed LS-SCLC underwent \[18F\]AlF-NOTA-QHY-04 PET/CT imaging prior to standard concurrent chemoradiotherapy. PET/CT parameters reflecting CXCR4 expression were measured and analyzed. Patients were subsequently followed up according to routine clinical practice. Clinical outcomes, including progression-free survival and overall survival, were recorded during follow-up. The association between baseline CXCR4 PET/CT imaging findings and clinical outcomes was evaluated to explore the potential role of CXCR4-targeted PET/CT as a prognostic imaging biomarker in LS-SCLC.
Study Type
OBSERVATIONAL
Enrollment
33
Shandong Cancer Hospital and Institute
Jinan, Shandong, China
Progression Status at 6 Months After Completion of Concurrent Chemoradiotherapy (CCRT)
Progression status assessed at 6 months after completion of concurrent chemoradiotherapy (CCRT) using imaging evaluation according to RECIST version 1.1. Participants were classified as having progression (Progressors) or no progression (Non-progressors).
Time frame: 6 months after completion of concurrent chemoradiotherapy (CCRT)
Progression-Free Survival (PFS)
Progression-free survival, defined as the time from study enrollment to disease progression (per RECIST version 1.1) or death from any cause, whichever occurred first.
Time frame: From date of enrollment until the date of first documented progression (per RECIST version 1.1) or date of death from any cause, whichever came first, assessed up to 36 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.